Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer

ARTICLES

Follow-up Confirms Apalutamide Survival Benefits in Some Men With Prostate Cancer

MEDSCAPE

PUBLISHED: 17 SEPTEMBER 2020

NEW YORK (Reuters Health) - Apalutamide markedly extends overall survival in patients with nonmetastatic castration-resistant prostate cancer (nmCRPC), according to a final analysis of data from the phase-3 SPARTAN study.